With the top-end stocks looking unexciting and overloved, investors have turned to the oft-maligned small caps sector for value.

It’s no easy gig analysing share prices and company performance but somebody’s got to do it. Every week two experts from our Share Tips columnist pool give us their recommendations. Recent changes in ...

The 2025 gold bull market hit new highs in September as the US Government hurtled towards a shutdown, while copper and uranium also gained.

The mineral sands market might have stalled but punters are still rewarding companies that are pushing their projects towards development.

Gold forecasts keep getting stronger, with Argonaut suggesting bullion could hit US$4500/oz by the end of 2027.

After five months of consecutive gains the ASX 200 fell 0.78% in September with nine of 11 sectors in the red.

The ASX did a solid job to close out the week, even as oil spilt and gold weighed (for a change). Techies were plugged in, though.

BHP has run headlong into a dispute with a powerful Chinese iron ore buyer, but the impact is yet to be felt on the ASX or iron ore prices.

Success in a ballot has given CGN Resources two tenements along strike from multi-million-ounce gold deposits in WA’s Leonora region.

Known for its nasal spray offering rapid onset to treat ED, LTR Pharma is expanding its portfolio while aiming for a swift ride to market.

US health regulators next week should clear PainChek's pain detection app for sale, thus culminating a complex five-year process.